文章核心观点 - 本文由Seeking Alpha平台上的Biotech Analysis Central服务作者Terry Chrisomalis撰写，专注于生物科技行业分析[1] - 作者提供付费订阅服务，月费49美元，年费399美元（享受33.50%折扣）[1] - 作者拥有应用科学背景，在生物科技领域有多年投资经验，管理包含600+生物科技投资文章和10+中小盘股模型组合的投资小组[2] 作者与平台背景 - 作者Terry Chrisomalis是Seeking Alpha Marketplace上Biotech Analysis Central服务的运营者[1] - 该服务提供深度制药公司分析，包含实时聊天、分析报告和新闻报告，帮助医疗保健投资者做出决策[2] - 作者声明在撰写本文时未持有任何提及公司的股票、期权或类似衍生品头寸，且72小时内无建仓计划[3] - 作者未从提及公司获得报酬，仅从Seeking Alpha获得稿费，与任何提及公司无业务关系[3] - Seeking Alpha声明过往业绩不保证未来结果，不提供投资建议或推荐，分析师观点不代表平台整体立场[4]

Pharvaris's experimental oral drug, deucrictibant, achieved an 83% reduction in hereditary angioedema (HAE) attack rates in its CHAPTER-3 Phase 3 study. Analyst firm Oppenheimer significantly increased its price target for Pharvaris to $75.00 from $50.00, reaffirming an "Outperform" rating. The positive clinical trial data and analyst confidence propelled Pharvaris's stock price, reaching a new 52-week high and boosting its market capitalization to approximately $2.64 billion.Pharvaris (NASDAQ: PHVS) is a ...